About NDC-1308 For Inducing Remyelination

A new drug with the potential to induce remyelination, the process for restoring and repairing the myelin sheath in demyelinating diseases including multiple sclerosis (MS), transverse myelitis and osmotic demyelination syndrome.

How the Body Makes Myelin


the body’s natural process for forming mature, myelinating oligodendrocytes leading to myelin sheaths. The process start from oligodendrocyte progenitor cells (OPCs) that are located throughout the central nervous system (CNS).

oligodendrogensis picture

NDC-1308 Induces the Body’s Natural System for Oligodendrogenisis

NDC-1308 is currently in late preclinical development, it is designed to address one of the root causes of demyelinating disease by inducing oligodendrocyte progenitor cells (OPCs) – the precursors of oligodendrocytes – to mature into oligodendrocytes, the cells that synthesize and maintain the myelin sheath.


Step 1:

Oligodendrocyte progenitor cells (OPCs) are present but quiescent



Designed to up-regulate key genes to induce remyelination


Step 2:

Gene activated by NDC-1308
Inducing Oligodendrogenisis


Step 3:

Pre-oligodendrocytes become pre-myelinating oligodendrocytes

Step 4:

Pre-myelinating oligodendrocytes become myelinating oligodendrocytes

A Multiple Target Approach

ENDECE is preparing to take NDC-1308 into clinical studies. Our scientists describe the dual mechanism of action that allows NDC-1308 to induce remyelination for treating diseases such as neuromyelitis optica (NMO), multiple sclerosis (MS), and Alzheimer’s disease.


  1. up-regulates lipoprotein lipase (LPL) expression causing a polarization in macrophages from the pro-inflammatory M1 like state to the anti-inflammatory, pro-repair state (M2-like phenotype); and
  2. turns on key genes within oligodendrocyte progenitor cells (OPCs) necessary for inducing OPCs to differentiate into mature oligodendrocytes which restore and maintain myelin sheaths.

The unique remyelinating activity of NDC-1308 comes from its ability to significantly up-regulate key genes necessary for OPC differentiation into mature oligodendrocytes.

NDC 1308 up regulates

Developing new drugs for diseases with limited or non-existent treatment options.